Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3.
Agarwal
R K
RK
Division of Allergy, Immunology, and Rheumatology, Children's Hospital of Buffalo, New York 14222.
Ostaszewski
M L
ML
Feld
L G
LG
Springate
J E
JE
Moxey-Mims
M M
MM
O'Neil
K M
KM
D000293:Adolescent; D001927:Brain Diseases / Q000134:cerebrospinal fluid / Q000209:etiology*; D005260:Female; D005334:Fever; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy; D006261:Headache; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015850:Interleukin-6 / Q000134:cerebrospinal fluid*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000209:etiology*; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D012640:Seizures / Q000134:cerebrospinal fluid / Q000209:etiology; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid*
D007166:Immunosuppressive Agents; D015850:Interleukin-6; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D008775:Methylprednisolone